Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital StrategiesStrategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital StrategyAgreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury StrategyPreclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation
